Dr Veronica Conca talks to ecancer at ASCO 2025 about data she presented from the phase III TRIPLETE study.

This evaluated whether intensifying first-line chemotherapy with modified FOLFOXIRI plus panitumumab (Pan) improved outcomes over standard FOLFOX/Pan in patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC).

Although the intensified regimen did not enhance response rate or progression-free survival (PFS) and was associated with greater gastrointestinal toxicity, overall survival (OS) was significantly longer in the FOLFOXIRI/Pan group, with a median OS of 41.1 months compared to 33.3 months in the FOLFOX/Pan group (HR: 0.79; p = 0.049).

These findings suggest that despite similar initial treatment activity, the intensified regimen provides a meaningful survival benefit, likely driven by improved post-progression outcomes.